Gilenya Could Surpass Avonex Market Share, Analysts Say
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis' Gilenya is fresh out of the gate, but stands to collect a large share of the MS market, Leerink Swann analysts predict in a report.